Cardiovascular Health in Menopause — MCQs
Which among the following is an absolute contraindication of Hormone replacement therapy?
The non-modifiable risk factor for hypertension is -
Estrogen administration in a menopausal woman increases the:
What is the effect of progesterone on lipids?
Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except
Which of the following is a beneficial effect of hormone replacement therapy in early menopause?
Senile vaginitis is due to :
What is the primary hormonal cause of hot flushes experienced during menopause?
In menopause, which of the following is seen:
HRT improves -
Cardiovascular Health in Menopause Indian Medical PG Practice Questions and MCQs
Question 1: Which among the following is an absolute contraindication of Hormone replacement therapy?
- A. Endometriosis
- B. Heart disease
- C. Breast carcinoma (Correct Answer)
- D. Osteoarthritis
Explanation: ### Breast carcinoma - Hormone replacement therapy (HRT) is **contraindicated** in breast carcinoma because many breast cancers are **estrogen-receptor positive**, meaning estrogen can stimulate their growth [1]. - Using HRT in patients with a history of breast cancer significantly increases the risk of **recurrence** or **progression** of the disease [1]. *Endometriosis* - Endometriosis is not an **absolute contraindication**; HRT can sometimes be used in women with a history of endometriosis, especially if a hysterectomy and bilateral oophorectomy have been performed. - However, unopposed estrogen therapy might **exacerbate** remaining endometrial implants, so a combined estrogen-progestin regimen is typically preferred [1]. *Heart disease* - While HRT has been shown to have **risks** in women with established coronary heart disease, it is not an absolute contraindication for all forms of heart disease. - The **Women's Health Initiative study** demonstrated increased cardiovascular events in older women initiating HRT, but current guidelines suggest that timing of initiation is crucial and benefits may outweigh risks for younger postmenopausal women. *Osteoarthritis* - Osteoarthritis is **not a contraindication** to HRT; in fact, some studies suggest that estrogen may have protective effects on cartilage [2]. - HRT is neither a treatment nor a contraindication for osteoarthritis and does not significantly impact its progression or severity [2].
Question 2: The non-modifiable risk factor for hypertension is -
- A. Environment stress
- B. Obesity
- C. Salt intake
- D. Age (Correct Answer)
Explanation: ***Age*** - Age is a **non-modifiable** risk factor because it is an inherent biological process that cannot be changed. [3] - The risk of developing **hypertension** generally increases with advancing age due to arterial stiffening and other physiological changes. [1] *Environment stress* - **Environmental stress** is considered a **modifiable** risk factor because individuals can learn coping mechanisms or make lifestyle changes to reduce its impact. - Chronic stress can lead to **sympathetic nervous system activation**, contributing to elevated blood pressure. [4] *Obesity* - **Obesity** is a **modifiable** risk factor, as it can be directly addressed through diet, exercise, and other lifestyle interventions. [2] - It increases the risk of hypertension by fostering **insulin resistance**, **inflammation**, and increased **cardiac output**. *Salt intake* - **Salt intake** is a **modifiable** risk factor as it can be controlled through dietary choices. [2] - Excessive sodium consumption can lead to **fluid retention** and increased blood volume, thereby raising blood pressure.
Question 3: Estrogen administration in a menopausal woman increases the:
- A. Bone mass (Correct Answer)
- B. Gonadotropin secretion
- C. Muscle mass
- D. LDL cholesterol
Explanation: ***Bone mass*** - Estrogen plays a crucial role in maintaining **bone density** by inhibiting osteoclast activity and promoting osteoblast function. - In menopausal women, estrogen administration counteracts bone loss and thus **increases bone mass**, reducing the risk of osteoporosis. *Gonadotropin secretion* - In menopausal women, **gonadotropin-releasing hormone (GnRH)** and subsequent **FSH and LH levels are elevated** due to the absence of ovarian estrogen feedback. - Estrogen administration would exert a **negative feedback** on the hypothalamus and pituitary, thereby **decreasing**, not increasing, gonadotropin secretion. *Muscle mass* - While estrogen has some anabolic effects, **androgens** (like testosterone) are the primary hormones responsible for significantly increasing muscle mass. - Estrogen administration to menopausal women is not a primary intervention for increasing muscle mass; its effects on this parameter are generally **modest or negligible**. *LDL cholesterol* - Estrogen generally has a **favorable effect on lipid profiles**, typically leading to a **decrease in LDL cholesterol** and an increase in HDL cholesterol. - Therefore, estrogen administration would generally **reduce**, not increase, LDL cholesterol levels.
Question 4: What is the effect of progesterone on lipids?
- A. Lowers HDL and lowers LDL
- B. Lowers HDL and increases LDL (Correct Answer)
- C. Lowers LDL, increases HDL
- D. Increases LDL and HDL
Explanation: ***Lowers HDL and increases LDL*** - This describes the effect of **synthetic progestins** (particularly older generation ones like levonorgestrel) on lipid profiles. - Synthetic progestins have been shown to **decrease HDL cholesterol** and **increase LDL cholesterol**, contributing to an unfavorable cardiovascular risk profile. - **Natural progesterone** has minimal or neutral effects on lipids, but this question refers to the progestin effects commonly discussed in contraceptive and hormone replacement therapy contexts. - This is the **classical teaching** for progesterone effects on lipids in most medical textbooks. *Lowers LDL, increases HDL* - This effect is characteristic of **estrogen**, not progesterone. - Estrogen improves lipid profiles by increasing HDL and lowering LDL cholesterol. - Progestins generally have opposite or antagonistic effects compared to estrogen on lipid metabolism. *Lowers HDL and lowers LDL* - While synthetic progestins do lower HDL, they typically **increase LDL**, not lower it. - A simultaneous decrease in both HDL and LDL is not a characteristic effect of progesterone or progestins. *Increases LDL and HDL* - Synthetic progestins tend to increase LDL, but they typically **lower HDL**, not increase it. - An increase in both LDL and HDL simultaneously is not a typical effect of progesterone on lipid metabolism.
Question 5: Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except
- A. Vaginal atrophy
- B. Osteoporosis
- C. Vasomotor symptoms
- D. Prevention of CAD (Correct Answer)
Explanation: ***Prevention of CAD*** - While HRT was initially thought to be cardioprotective, large-scale studies like the **Women's Health Initiative (WHI)** demonstrated that it does **not prevent coronary artery disease (CAD)** and may even increase the risk of cardiovascular events, especially in older postmenopausal women or those initiating therapy years after menopause. - The potential benefits regarding CAD prevention are outweighed by risks such as **stroke** and **venous thromboembolism**. *Vaginal atrophy* - **Estrogen deficiency** in postmenopausal women leads to thinning, dryness, and inflammation of the vaginal walls, causing symptoms like dryness, irritation, and painful intercourse. - **Local or systemic estrogen therapy** effectively reverses these changes by restoring vaginal tissue health. *Osteoporosis* - **Bone loss** accelerates after menopause due to declining estrogen levels, increasing the risk of osteoporosis and fractures. - HRT, particularly estrogen, is effective in **preventing and treating osteoporosis** by inhibiting bone resorption and preserving bone mineral density. *Vasomotor symptoms* - **Hot flashes** and **night sweats** are common and often debilitating symptoms of menopause, directly linked to fluctuating and declining estrogen levels. - HRT, especially systemic estrogen, is the **most effective treatment** for alleviating these symptoms by stabilizing thermoregulatory control.
Question 6: Which of the following is a beneficial effect of hormone replacement therapy in early menopause?
- A. Increased Endothelin
- B. Increased TNF-α
- C. Increased Nitric oxide (Correct Answer)
- D. Decreased COX-2
Explanation: ***Increased Nitric oxide*** - **Estrogen** in HRT increases the production and bioavailability of **nitric oxide (NO)** by upregulating endothelial nitric oxide synthase (eNOS). - Increased NO leads to **vasodilation**, contributing to cardiovascular benefits and improved endothelial function. *Increased Endothelin* - **Endothelin-1** is a potent vasoconstrictor, and increased levels are generally associated with **endothelial dysfunction** and cardiovascular risk. - HRT, particularly estrogen, tends to decrease endothelin-1 levels or counteract its effects, leading to beneficial vascular responses. *Increased TNF-α* - **Tumor Necrosis Factor-alpha (TNF-α)** is a pro-inflammatory cytokine, and elevated levels are linked to chronic inflammation and increased risk of various diseases. - HRT, especially estrogen, typically has **anti-inflammatory effects**, potentially reducing TNF-α levels or mitigating its inflammatory actions. *Decreased COX-2* - **Cyclooxygenase-2 (COX-2)** is an enzyme involved in inflammation and pain pathways; its decrease is generally anti-inflammatory. - However, the primary beneficial vascular effect of HRT is not through direct inhibition of COX-2 but rather through mechanisms like increasing nitric oxide.
Question 7: Senile vaginitis is due to :
- A. Diabetes
- B. Gonococcal infection
- C. Oestrogen deficiency (Correct Answer)
- D. Cancer cervix
Explanation: ***Oestrogen deficiency*** - **Senile vaginitis**, also known as **atrophic vaginitis**, is primarily caused by **decreased oestrogen levels**, particularly after menopause. - Reduced oestrogen leads to thinning and drying of the vaginal walls, making them more susceptible to inflammation and infection. *Diabetes* - While uncontrolled **diabetes** can increase the risk of vaginal infections, such as **candidiasis**, it is not the direct cause of senile vaginitis itself. - Diabetic neuropathy can affect vaginal sensation, but does not cause the atrophic changes observed in senile vaginitis. *Gonococcal infection* - **Gonococcal infection** is a sexually transmitted infection that causes acute inflammation of the mucous membranes, but not the long-term atrophic changes seen in senile vaginitis. - It would present with purulent discharge and dysuria, which are distinct from the symptoms of senile vaginitis. *Cancer cervix* - **Cervical cancer** is a malignancy of the cervix and does not directly cause senile vaginitis. - While it can manifest with abnormal vaginal bleeding or discharge, these symptoms are typically due to the tumor itself and not the atrophic changes characteristic of senile vaginitis.
Question 8: What is the primary hormonal cause of hot flushes experienced during menopause?
- A. Increased noradrenaline with normal estrogen levels
- B. Increased noradrenaline
- C. Decreased estrogen levels (Correct Answer)
- D. Both increased noradrenaline and decreased estrogen levels
Explanation: ***Decreased estrogen levels*** - **Decreased estrogen** is the primary hormonal change during menopause, leading to thermoregulatory dysfunction in the hypothalamus. - This hormonal imbalance causes the **vasomotor symptoms** like hot flushes and night sweats. *Increased noradrenaline* - While **noradrenaline** (norepinephrine) is involved in thermoregulation, its increase is a **secondary event** triggered by the initial estrogen deficiency, not the primary cause. - Increased noradrenaline can exacerbate the **vasodilation** and heat dissipation experienced during a hot flush. *Increased noradrenaline with normal estrogen levels* - This option is incorrect because hot flushes are characteristic of menopause, which is defined by **decreased estrogen levels**. - **Normal estrogen levels** would typically prevent the severe thermoregulatory instability that causes hot flushes. *Both increased noradrenaline and decreased estrogen levels* - Although both factors are involved, the question asks for the **primary hormonal cause**. **Decreased estrogen** initiates the cascade of events, including the subsequent alteration of neurotransmitter levels like noradrenaline. - Noradrenaline's role is more of a **mediator** in the physiological response to the primary estrogen deficiency.
Question 9: In menopause, which of the following is seen:
- A. High FSH (Correct Answer)
- B. High progesterone
- C. High estrogen
- D. Low FSH
Explanation: ***High FSH*** - In **menopause**, the ovaries lose their ability to produce **estrogen** and **progesterone**, leading to a decline in their levels. - This decline in ovarian hormones removes the **negative feedback** on the **hypothalamus** and **anterior pituitary**, causing a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, **follicle-stimulating hormone (FSH)**, and **luteinizing hormone (LH)**. *High progesterone* - **Progesterone** levels are typically **low** in menopause because the ovaries are no longer ovulating or producing the corpus luteum, which is the primary source of progesterone. - While progesterone is important in the normal menstrual cycle, its production ceases after the final menstrual period. *High estrogen* - **Estrogen** levels are generally **low** in menopause due to the cessation of ovarian follicular activity. - The decline in estrogen is responsible for many menopausal symptoms, such as hot flashes and vaginal dryness. *Low FSH* - **Low FSH** is typically seen in conditions where there is sufficient **estrogen** and **progesterone** exerting negative feedback on the pituitary, or in primary pituitary/hypothalamic dysfunction. - In menopause, the **lack of ovarian hormones** specifically causes FSH (and LH) levels to be significantly elevated.
Question 10: HRT improves -
- A. Dementia
- B. Coronary artery disease
- C. Bone density (Correct Answer)
- D. Endometrial cancer risk
Explanation: ***Bone density*** - **Hormone replacement therapy (HRT)** effectively prevents bone loss and reduces the risk of **osteoporosis** and fractures in postmenopausal women. - **Estrogen** plays a crucial role in maintaining bone density by inhibiting osteoclast activity and promoting osteoblast activity. *Dementia* - Studies have shown that HRT does not improve or prevent dementia and may even increase the risk of cognitive decline in older women. - The timing of HRT initiation relative to menopause may influence its effect on cognitive function, with later initiation potentially being less beneficial or even harmful. *Coronary artery disease* - While earlier beliefs suggested HRT might be protective, large clinical trials have demonstrated that HRT does not reduce the risk of **coronary artery disease** and may even increase it in some populations. - The effects on cardiovascular health are complex and depend on factors such as age, time since menopause, and individual risk factors. *Endometrial cancer risk* - **Unopposed estrogen** HRT significantly increases the risk of **endometrial cancer**. - This risk is mitigated by combining estrogen with **progestin** in women with an intact uterus.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free